TILT Biotherapeutics Announces Data at ESMO on Its Oncolytic Immunotherapy Platform

On September 17, 2021 TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, reported that the company presented yesterday clinical study results at the annual congress of the European Society of Molecular Oncology (ESMO) (Free ESMO Whitepaper) (Press release, TILT Biotherapeutics, SEP 17, 2021, View Source [SID1234587847]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ESMO (Free ESMO Whitepaper) poster (1), presented by TILT with collaborators at the National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University, and CHU Nantes, provided an update on the company’s progress with its TILT-123 oncolytic immunotherapy asset designed to stimulate T-cells, currently in clinical trials in Denmark and France for metastatic melanoma.

Interim data from six patients shows that TILT-123 monotherapy or a combination of TILT-123 and tumor-infiltrating lymphocytes (TILs) is deemed safe with the lowest two dose levels of TILT-123. Also, the company’s engineered oncolytic virus appears to be highly tumor specific, as extended replication in tumors was seen even at the lowest dose level, without quantifiable shedding into saliva or urine.

TILT Biotherapeutics’ CEO, Akseli Hemminki, a biotech entrepreneur and oncologist who has personally treated 300 patients with eleven different oncolytic viruses, said, "The annual ESMO (Free ESMO Whitepaper) congress is one of the world’s most prestigious oncology events, and I am delighted we were able to present there about recent progress with our oncolytic immunotherapy platform. We have now proceeded to the third dose level in our T215 and T115 trials, with patients in France, Denmark, and Finland."

(1) Poster title and link: "A phase I, first-in-human, study of TILT-123, a tumor-selective oncolytic adenovirus encoding TNFa and IL-2, in participants with advanced melanoma receiving adoptive T-cell therapy with tumor-infiltrating lymphocytes." The clinical trial details are here.